Patents by Inventor Xin Xiao Zheng
Xin Xiao Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9346876Abstract: The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.Type: GrantFiled: April 29, 2014Date of Patent: May 24, 2016Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Vijay K. Kuchroo, Terry Barton Strom, Eugene K. Cha, Sumone Chakravarti, Catherine Anne Sabatos-Peyton, Chen Zhu, Xin Xiao Zheng, Alberto Sanchez-Fueyo
-
Publication number: 20150079085Abstract: The invention relates to methods of modulating immune responses in a subject such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.Type: ApplicationFiled: October 1, 2014Publication date: March 19, 2015Inventors: Vijay K. Kuchroo, Sumone Chakravarti, Terry Strom, Xin Xiao Zheng, Jennifer Meyers
-
Publication number: 20140348842Abstract: The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.Type: ApplicationFiled: April 29, 2014Publication date: November 27, 2014Applicants: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Vijay K. Kuchroo, Terry Strom, Eugene K. Cha, Sumone Chakravarti, Catherine Sabatos, Chen Zhu, Xin Xiao Zheng, Alberto Sanchez-Fueyo
-
Patent number: 8329660Abstract: The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.Type: GrantFiled: October 4, 2004Date of Patent: December 11, 2012Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Vijay K. Kuchroo, Terry Strom, Eugene K. Cha, Sumone Chakravarti, Catherine Sabatos, Chen Zhu, Xin Xiao Zheng, Alberto Sanchez-Fueyo
-
Publication number: 20110045002Abstract: The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.Type: ApplicationFiled: April 26, 2010Publication date: February 24, 2011Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Vijay K. Kuchroo, Sumone Chakravarti, Terry Strom, Xin Xiao Zheng, Jennifer Hartt Meyers
-
Publication number: 20100291054Abstract: The invention provides isolated regulatory T cells and methods of obtaining regulatory T cells. The invention also provides methods for inhibiting an antigen-specific immune response (e.g., graft rejection, an autoimmune disorder, graft versus host disease, a response to a tumor cell, a response to an infection, and a response to an allergen) in a subject requiring administering an isolated regulatory T cell to the subject. The invention further provides methods for treating or modulating an antigen-specific immune response in a subject requiring administering a regulatory T cell to the subject.Type: ApplicationFiled: November 28, 2007Publication date: November 18, 2010Applicant: BETH ISRAEL DEACONESS MEDICAL CENTERInventors: Xin Xiao Zheng, Dong Zhang
-
Patent number: 7741271Abstract: The invention relates to methods of modulating immune responses in a subject, such as by administering to the subject agents which modulate tim-1, tim-2 or tim-4 activity, or which modulate the physical interaction between tim-1 and tim-4 or between tim-2 and a tim-2 ligand. Immune responses include, but are not limited to, autoimmune disorders, transplantation tolerance, and Th1 and Th2-mediated responses and disorders. The invention also relates to novel assays for identifying agents which modulate the physical interaction between tim-1 and tim-4. In addition, the invention relates to novel soluble tim-4 polypeptides and to nucleic acids which encode them.Type: GrantFiled: March 14, 2005Date of Patent: June 22, 2010Assignees: The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Vijay K. Kuchroo, Sumone Chakravarti, Terry Strom, Xin Xiao Zheng, Jennifer Meyers
-
Patent number: 7579439Abstract: The present invention is based, in part, on expression studies of IL-2 and IL-15 receptor subunits by cycling T cells in vivo. In one embodiment, the invention generally features novel combinations of IL-2 and IL-15 antagonists and methods of suppressing the immune response by administering these antagonists. In each case, suppression is achieved by administration of a first agent that targets an IL-15 molecule or an IL-15 receptor (IL-15R) and a second agent that targets an IL-2 molecule or an IL-2 receptor (IL-2R). More generally, the invention features novel combinations of agents that, when administered to a patient (or to a transplant ex vivo), reduce the number of antigen-reactive T cells. For example, the invention features compositions (e.g., pharamaceutically acceptable compositions) that include two or more agents, each of which promote T cell death. Alternatively, the composition can contain at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation.Type: GrantFiled: December 30, 2003Date of Patent: August 25, 2009Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Terry B. Strom, Xian Chang Li, Xin Xiao Zheng
-
Publication number: 20080089894Abstract: The invention relates to methods of inducing tolerance and preventing transplant rejection by blocking costimulatory signals and using immunosuppressive agents, preferably rapamycin, to prevent late rejection episodes, yet not block tolerance inducing T-cell specific depletion; compositions and kits for use in such methods are also provided herein.Type: ApplicationFiled: December 5, 2007Publication date: April 17, 2008Inventors: Terry Strom, Xin Xiao Zheng
-
Patent number: 7347995Abstract: Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.Type: GrantFiled: May 25, 2004Date of Patent: March 25, 2008Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Terry B. Strom, Wlodzimierz Maslinski, Xin Xiao Zheng, Yon Su Kim, Sylvie Ferrari-Lacraz
-
Patent number: 7018626Abstract: Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e.g., multiple myeloma) in a patient.Type: GrantFiled: May 14, 2002Date of Patent: March 28, 2006Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
-
Publication number: 20040219148Abstract: Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.Type: ApplicationFiled: May 25, 2004Publication date: November 4, 2004Applicant: Beth Israel Deaconess Medical Center, Inc., a Massachusetts corporationInventors: Terry B. Strom, Wlodzimierz Maslinski, Xin Xiao Zheng, Yon Su Kim, Sylvie Ferrari-Lacraz
-
Patent number: 6797263Abstract: Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.Type: GrantFiled: May 14, 2001Date of Patent: September 28, 2004Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Terry B. Strom, Wlodzimierz Maslinski, Xin Xiao Zheng, Yon Su Kim, Sylvie Ferrari-Lacraz
-
Patent number: 6770272Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.Type: GrantFiled: May 14, 2002Date of Patent: August 3, 2004Assignee: Beth Israel Hospital AssociationInventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
-
Publication number: 20030026778Abstract: Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e.g., multiple myeloma) in a patient.Type: ApplicationFiled: May 14, 2002Publication date: February 6, 2003Applicant: Beth Israel Hospital Association, a Massachusetts corporationInventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
-
Publication number: 20020173628Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.Type: ApplicationFiled: May 14, 2002Publication date: November 21, 2002Applicant: Beth Israel Hospital AssociationInventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
-
Publication number: 20020128436Abstract: Disclosed herein are therapeutic compositions containing agents that modulate the immune response in a patient.Type: ApplicationFiled: May 14, 2001Publication date: September 12, 2002Inventors: Terry B. Strom, Wlodzimierz Maslinski, Xin Xiao Zheng, Yon Su Kim, Sylvie Ferrari Lacraz
-
Patent number: 6410008Abstract: Disclosed are chimeric proteins having IL-10 fused to an enzymatically inactive polypeptide which increases the circulating half-life of IL-10. The chimeric polypeptides are useful for treating or preventing septic shock, inhibiting the development of Type I diabetes, and treating multiple myeloma in a patient.Type: GrantFiled: December 12, 1994Date of Patent: June 25, 2002Assignee: Beth Israel Hospital AssociationInventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele
-
Patent number: 6403077Abstract: Disclosed are chimeric proteins having a cytokine fused to an enzymatically inactive polypeptide which increases the circulating half-life of the cytokine. The chimeric proteins are useful for treating, inhibiting, or preventing a variety of conditions, including septic shock, granulomatous disorders, Type I diabetes, and various cancers (e.g., multiple myeloma) in a patient.Type: GrantFiled: November 6, 1997Date of Patent: June 11, 2002Assignee: Beth Israel Hospital AssociationInventors: Terry B. Strom, Xin Xiao Zheng, Alan Steele